<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00549939</url>
  </required_header>
  <id_info>
    <org_study_id>EFC5722</org_study_id>
    <secondary_id>2004-002397-38</secondary_id>
    <nct_id>NCT00549939</nct_id>
  </id_info>
  <brief_title>Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction</brief_title>
  <acronym>ALFACHIN</acronym>
  <official_title>12-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy, Pharmacodynamic and Safety of 2 Doses of Alfuzosin (0.1 mg/kg/Day, 0.2 mg/kg/Day) in the Treatment of Children and Adolescents 2-16 Years With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Followed by a 40-week Open-label Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study was to evaluate the efficacy of Alfuzosin in comparison to
      Placebo on the detrusor Leak Point Pressure (LPP) in children and adolescents 2-16 years of
      age with elevated detrusor LPP of neuropathic etiology and detrusor LPP ≥ 40 cm H2O.

      Secondary objectives were:

        -  To investigate the safety and tolerability of two doses of Alfuzosin in comparison to
           Placebo in children and adolescents,

        -  To evaluate the effects of the two doses of Alfuzosin in comparison to Placebo on:

             -  Detrusor compliance,

             -  Urinary tract infection,

        -  To investigate the pharmacokinetics of Alfuzosin (population kinetics),

        -  To evaluate the 12-month long-term safety of Alfuzosin 0.1 mg/kg/day and 0.2 mg/kg/day.

      The study consisted of 2 periods:

        -  a 12-week double blind treatment period where patients were to receive either Alfuzosin
           0.1 mg/kg/day or Alfuzosin 0.2 mg/kg/day or placebo then,

        -  a 40-week open label extension treatment period where patients were to receive either
           Alfuzosin 0.1 mg/kg/day or Alfuzosin 0.2 mg/kg/day.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who met the study entry criteria were randomized (2:1:2:1) to one of the 4 dosage
      groups (Alfuzosin 0.1 mg/kg/day, matching placebo 0.1 mg/kg/day, Alfuzosin 0.2 mg/mg/kg,
      matching placebo 0.2 mg/kg/day).

      Patients received their treatment using either solution or tablet formulation depending on
      age as follows:

        -  Solution to children 2-7 years of age or, children and adolescents 8-16 years of age if
           they were unable to swallow tablets or they preferred to take the solution or if they
           had a body weight &lt; 30kg. The daily dose was devided in 3 doses given at at breakfast,
           lunch and dinner.

        -  Tablet to children and adolescents 8-16 years of age who were able to swallow tablets
           and had a body weight ≥ 30kg. The daily dose was devided in 2 doses given at at
           breakfast and dinner.

      Patients who have completed the 12-week double-blind phase were offered to continue in the
      40-week open-label extension study.

        -  Patients receiving Alfuzosin continued with their dosing regimen.

        -  Patients receiving Placebo were switched to Alfuzosin with a dose corresponding to their
           randomization dose group.

      All patients had a one-week follow-up period after last dose intake.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Detrusor Leak Point Pressure (LPP) &lt; 40 cm H2O</measure>
    <time_frame>12 weeks (double blind treatment period)</time_frame>
    <description>Detrusor Leak Point Pressure (LPP) was measured by cystometry.
For each measure, 2 or 3 cystometries were carried out depending on the difference between the 2 first LPP values (if the difference ≥ 20 cm H2O, a 3rd cystometry was done). The lowest value was retained.
Investigators reading was then consolidated by the review of all cystometry data by 2 external &quot;Expert Reviewers&quot;, who were blinded for the study treatment.
The analysis was performed on consolidated investigators data (i.e. endorsed by the Investigator taking into account reviewers opinion).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detrusor Leak Point Pressure (LPP)</measure>
    <time_frame>baseline and 12 weeks (double blind treatment period)</time_frame>
    <description>Detrusor Leak Point Pressure (LPP) was assessed at baseline and 12 weeks as described for the primary outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Detrusor LPP</measure>
    <time_frame>12 weeks ((double blind treatment period)</time_frame>
    <description>Absolute change = Detrusor LPP at 12 weeks - Detrusor LPP at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change in Detrusor LPP</measure>
    <time_frame>12 weeks (double blind treatment period)</time_frame>
    <description>Relative change = 100 * (Detrusor LPP at 12 weeks - Detrusor LPP at baseline) / Detrusor LPP at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detrusor Compliance</measure>
    <time_frame>baseline and 12 weeks (double blind treatment period)</time_frame>
    <description>Detrusor compliance is defined as the relationship between change in detrusor volume and change in detrusor pressure.
It was calculated by dividing the volume change (ΔV) by the change in detrusor pressure (Δpdet) during that change in detrusor volume at leak point (C= ΔV/Δpdet).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change in Detrusor Compliance</measure>
    <time_frame>12 weeks (double blind treatment period)</time_frame>
    <description>Relative change = 100 * (Detrusor compliance at 12 weeks - Detrusor compliance at baseline) / Detrusor compliance at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Symptomatic Urinary Tract Infection (UTI) Episodes</measure>
    <time_frame>12 weeks (double blind treatment period)</time_frame>
    <description>When a patient presented with symptoms such as pain, fever or hematuria (discretion of the Investigator), an urinalysis was performed including a dipstick and a quantitative urine culture.
A symptomatic UTI was defined as the presence of symptoms and a positive culture with &gt; 100 000 Colony Forming Units (CFUs) with a single organism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Symptomatic Urinary Tract Infection (UTI) Episodes</measure>
    <time_frame>52 weeks (double blind treatment period + open label extension treatment period)</time_frame>
    <description>Symptomatic UTI episodes were assessed similar to the previous outcome measure but for a longer follow-up period.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Neurogenic Urinary Bladder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo 0.1 mg/kg/day or 0.2 mg/kg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alfuzosin 0.1 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alfuzosin 0.2 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfuzosin</intervention_name>
    <description>Form: solution or tablet according to age
Route: oral
Dose: daily dose adjusted to body weight</description>
    <arm_group_label>Alfuzosin 0.1 mg/kg/day</arm_group_label>
    <arm_group_label>Alfuzosin 0.2 mg/kg/day</arm_group_label>
    <other_name>SL770499</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Form: matching solution or matching tablet according to age
Route: oral
Dose: daily dose adjusted to body weight</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with elevated detrusor Leak Point Pressure (LPP) of neuropathic etiology and
             Detrusor LPP ≥ 40 cm H2O and &lt; 100 cm H2O.

        Exclusion Criteria:

          -  Urological surgery in the last 4 months prior to the study,

          -  Patients who have urethral dilatation in the last 3 months prior to the baseline
             urodynamic assessment,

          -  α-blocker therapy in the last 4 weeks prior to the baseline urodynamic assessment,

          -  Detrusor injections of botulinum toxin in the last 6 months,

          -  Urological diseases/conditions other than functional bladder obstruction of
             neuropathic etiology that can lead to upper urinary tract dilatation (e.g., bladder
             anomalies, ureterocele),

          -  History of intolerance to α-blocker therapy,

          -  Orthostatic hypotension,

          -  History of risk factors for Torsade de pointes (e.g., family history of Long QT
             Syndrome).

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Makati City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Porto Salvo</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Aministrative Office</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2007</study_first_submitted>
  <study_first_submitted_qc>October 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2007</study_first_posted>
  <results_first_submitted>January 13, 2011</results_first_submitted>
  <results_first_submitted_qc>January 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 8, 2011</results_first_posted>
  <disposition_first_submitted>March 8, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>March 8, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 9, 2010</disposition_first_posted>
  <last_update_submitted>October 21, 2014</last_update_submitted>
  <last_update_submitted_qc>October 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>child</keyword>
  <keyword>bladder</keyword>
  <keyword>neuropathic</keyword>
  <keyword>alpha blockers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alfuzosin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 55 sites in 18 countries. A total of 261 patients were screened between September 2007 and November 2008.</recruitment_details>
      <pre_assignment_details>172/261 patients were randomized in the 12-week double blind phase.
89/261 patients were not randomized for the following reasons:
Adverse event (1 patient*),
Inclusion/Exclusion criteria not met (69 patients*),
Subject's request (11 patients*),
Other (13 patients*).
'*' Patients could have several reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Alfuzosin 0.1 mg/kg/day matching placebo or Alfuzosin 0.2 mg/kg/day matching placebo</description>
        </group>
        <group group_id="P2">
          <title>Alfuzosin 0.1 mg/kg/Day</title>
        </group>
        <group group_id="P3">
          <title>Alfuzosin 0.2 mg/kg/Day</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>12-week Double Blind Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57">29 (Alfuzosin 0.1 mg/kg/day matching placebo) + 28 (Alfuzosin 0.2 mg/kg/day matching placebo)</participants>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Too many blood draws</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>40-week Open Label Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">54 patients continued and switched to Alfuzosin: 26 to 0.1 mg/kg/day and 28 to 0.2 mg/kg/day.</participants>
                <participants group_id="P2" count="80">54 patients continued Alfuzosin 0.1 mg/kg/day and 26 patients started Alfuzosin 0.1 mg/kg/day.</participants>
                <participants group_id="P3" count="83">55 patients continued Alfuzosin 0.2 mg/kg/day and 28 patients started Alfuzosin 0.2 mg/kg/day.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Alfuzosin 0.1 mg/kg/day matching placebo or Alfuzosin 0.2 mg/kg/day matching placebo</description>
        </group>
        <group group_id="B2">
          <title>Alfuzosin 0.1 mg/kg/Day</title>
        </group>
        <group group_id="B3">
          <title>Alfuzosin 0.2 mg/kg/Day</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="57"/>
            <count group_id="B3" value="58"/>
            <count group_id="B4" value="172"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.3" spread="4.4"/>
                    <measurement group_id="B2" value="7.9" spread="3.9"/>
                    <measurement group_id="B3" value="8.7" spread="3.9"/>
                    <measurement group_id="B4" value="8.3" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinary Tract Infection (UTI) history in the last 3 months</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No UTI episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>One UTI episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two UTI episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Study drug formulation</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Solution (2-7 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solution (8-16 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tablets (8-16 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Detrusor Leak Point Pressure (LPP) &lt; 40 cm H2O</title>
        <description>Detrusor Leak Point Pressure (LPP) was measured by cystometry.
For each measure, 2 or 3 cystometries were carried out depending on the difference between the 2 first LPP values (if the difference ≥ 20 cm H2O, a 3rd cystometry was done). The lowest value was retained.
Investigators reading was then consolidated by the review of all cystometry data by 2 external &quot;Expert Reviewers&quot;, who were blinded for the study treatment.
The analysis was performed on consolidated investigators data (i.e. endorsed by the Investigator taking into account reviewers opinion).</description>
        <time_frame>12 weeks (double blind treatment period)</time_frame>
        <population>The Intent-to-treat (ITT) population was used for the analysis. All randomized patients were included in the analysis in the treatment group to which they were allocated as per randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Alfuzosin 0.1 mg/kg/day matching placebo or Alfuzosin 0.2 mg/kg/day matching placebo</description>
          </group>
          <group group_id="O2">
            <title>Alfuzosin 0.1 mg/kg/Day</title>
          </group>
          <group group_id="O3">
            <title>Alfuzosin 0.2 mg/kg/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Detrusor Leak Point Pressure (LPP) &lt; 40 cm H2O</title>
          <description>Detrusor Leak Point Pressure (LPP) was measured by cystometry.
For each measure, 2 or 3 cystometries were carried out depending on the difference between the 2 first LPP values (if the difference ≥ 20 cm H2O, a 3rd cystometry was done). The lowest value was retained.
Investigators reading was then consolidated by the review of all cystometry data by 2 external &quot;Expert Reviewers&quot;, who were blinded for the study treatment.
The analysis was performed on consolidated investigators data (i.e. endorsed by the Investigator taking into account reviewers opinion).</description>
          <population>The Intent-to-treat (ITT) population was used for the analysis. All randomized patients were included in the analysis in the treatment group to which they were allocated as per randomization.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 40 cmH2O (&quot;Success&quot;)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 40 cmH2O or missing (&quot;Failure&quot;)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <p_value_desc>P-value was adjusted for multiplicity using the Hochberg procedure. The a priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.91</p_value>
            <p_value_desc>P-value was adjusted for multiplicity using the Hochberg procedure. The a priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Detrusor Leak Point Pressure (LPP)</title>
        <description>Detrusor Leak Point Pressure (LPP) was assessed at baseline and 12 weeks as described for the primary outcome measure.</description>
        <time_frame>baseline and 12 weeks (double blind treatment period)</time_frame>
        <population>The analysis was performed on the Intent-to-treat (ITT) population excluding the patients who didn't have baseline and/or post-baseline LPP values. Patients were included in the treatment group to which they were allocated as per randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Alfuzosin 0.1 mg/kg/Day</title>
          </group>
          <group group_id="O3">
            <title>Alfuzosin 0.2 mg/kg/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Detrusor Leak Point Pressure (LPP)</title>
          <description>Detrusor Leak Point Pressure (LPP) was assessed at baseline and 12 weeks as described for the primary outcome measure.</description>
          <population>The analysis was performed on the Intent-to-treat (ITT) population excluding the patients who didn't have baseline and/or post-baseline LPP values. Patients were included in the treatment group to which they were allocated as per randomization.</population>
          <units>cmH2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2" spread="12.6"/>
                    <measurement group_id="O2" value="53.3" spread="13.4"/>
                    <measurement group_id="O3" value="50.9" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2" spread="23.4"/>
                    <measurement group_id="O2" value="41.6" spread="18.2"/>
                    <measurement group_id="O3" value="39.4" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Detrusor LPP</title>
        <description>Absolute change = Detrusor LPP at 12 weeks - Detrusor LPP at baseline</description>
        <time_frame>12 weeks ((double blind treatment period)</time_frame>
        <population>The analysis was performed on the same population as previously (i.e. ITT population excluding the patients who didn't have baseline and/or post-baseline value).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Alfuzosin 0.1 mg/kg/Day</title>
          </group>
          <group group_id="O3">
            <title>Alfuzosin 0.2 mg/kg/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Detrusor LPP</title>
          <description>Absolute change = Detrusor LPP at 12 weeks - Detrusor LPP at baseline</description>
          <population>The analysis was performed on the same population as previously (i.e. ITT population excluding the patients who didn't have baseline and/or post-baseline value).</population>
          <units>cmH2O</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="2.8"/>
                    <measurement group_id="O2" value="-11.7" spread="2.8"/>
                    <measurement group_id="O3" value="-12.5" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in detrusor LPP was analyzed using a three-way analysis of covariance (ANCOVA) including 3 variables as fixed effects:
treatment group (alfuzosin 0.1 mg/kg/day, alfuzosin 0.2 mg/kg/day or placebo),
age/formulation group (2-7 years of age on solution, 8-16 years of age on solution or 8-16 years of age on tablets),
anticholinergic/antimuscarinic use (yes or no),
and using centered baseline detrusor LPP as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1040</p_value>
            <p_value_desc>P-value was adjusted for multiplicity using the Hochberg procedure. The a priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean difference versus Placebo</param_type>
            <param_value>-6.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.80</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.72</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1040</p_value>
            <p_value_desc>P-value was adjusted for multiplicity using the Hochberg procedure. The a priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean difference versus Placebo</param_type>
            <param_value>-7.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.51</ci_lower_limit>
            <ci_upper_limit>0.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change in Detrusor LPP</title>
        <description>Relative change = 100 * (Detrusor LPP at 12 weeks - Detrusor LPP at baseline) / Detrusor LPP at baseline</description>
        <time_frame>12 weeks (double blind treatment period)</time_frame>
        <population>The analysis was performed on the same population as previously (i.e. ITT population excluding the patients who didn't have baseline and/or post-baseline value).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Alfuzosin 0.1 mg/kg/Day</title>
          </group>
          <group group_id="O3">
            <title>Alfuzosin 0.2 mg/kg/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Relative Change in Detrusor LPP</title>
          <description>Relative change = 100 * (Detrusor LPP at 12 weeks - Detrusor LPP at baseline) / Detrusor LPP at baseline</description>
          <population>The analysis was performed on the same population as previously (i.e. ITT population excluding the patients who didn't have baseline and/or post-baseline value).</population>
          <units>percentage of cmH2O</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="5.53"/>
                    <measurement group_id="O2" value="-20.6" spread="5.56"/>
                    <measurement group_id="O3" value="-23.5" spread="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in detrusor LPP was analyzed using a three-way analysis of covariance (ANCOVA) including 3 variables as fixed effects:
treatment group (alfuzosin 0.1 mg/kg/day, alfuzosin 0.2 mg/kg/day or placebo),
age/formulation group (2-7 years of age on solution, 8-16 years of age on solution or 8-16 years of age on tablets),
anticholinergic/antimuscarinic use (yes or no),
and using centered baseline detrusor LPP as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1338</p_value>
            <p_value_desc>P-values was adjusted for multiplicity using the Hochberg procedure. The a priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean difference versus Placebo</param_type>
            <param_value>-11.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.27</ci_lower_limit>
            <ci_upper_limit>3.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1152</p_value>
            <p_value_desc>P-value was adjusted for multiplicity using the Hochberg procedure. The a priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean difference versus Placebo</param_type>
            <param_value>-14.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.10</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Detrusor Compliance</title>
        <description>Detrusor compliance is defined as the relationship between change in detrusor volume and change in detrusor pressure.
It was calculated by dividing the volume change (ΔV) by the change in detrusor pressure (Δpdet) during that change in detrusor volume at leak point (C= ΔV/Δpdet).</description>
        <time_frame>baseline and 12 weeks (double blind treatment period)</time_frame>
        <population>The analysis was performed on the intent-to-treat (ITT) population excluding the patients who didn't have baseline and/or post baseline detrusor compliance values. Patients were included in the treatment group to which they were allocated as per randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Alfuzosin 0.1 mg/kg/Day</title>
          </group>
          <group group_id="O3">
            <title>Alfuzosin 0.2 mg/kg/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Detrusor Compliance</title>
          <description>Detrusor compliance is defined as the relationship between change in detrusor volume and change in detrusor pressure.
It was calculated by dividing the volume change (ΔV) by the change in detrusor pressure (Δpdet) during that change in detrusor volume at leak point (C= ΔV/Δpdet).</description>
          <population>The analysis was performed on the intent-to-treat (ITT) population excluding the patients who didn't have baseline and/or post baseline detrusor compliance values. Patients were included in the treatment group to which they were allocated as per randomization.</population>
          <units>mL/cmH20</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="2.8"/>
                    <measurement group_id="O2" value="3.4" spread="2.8"/>
                    <measurement group_id="O3" value="3.3" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="5.0"/>
                    <measurement group_id="O2" value="5.3" spread="4.9"/>
                    <measurement group_id="O3" value="5.8" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change in Detrusor Compliance</title>
        <description>Relative change = 100 * (Detrusor compliance at 12 weeks - Detrusor compliance at baseline) / Detrusor compliance at baseline</description>
        <time_frame>12 weeks (double blind treatment period)</time_frame>
        <population>The analysis was performed on the same population as previously (i.e. ITT population excluding the patients who didn't have baseline and/or post-baseline value).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Alfuzosin 0.1 mg/kg/Day</title>
          </group>
          <group group_id="O3">
            <title>Alfuzosin 0.2 mg/kg/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Relative Change in Detrusor Compliance</title>
          <description>Relative change = 100 * (Detrusor compliance at 12 weeks - Detrusor compliance at baseline) / Detrusor compliance at baseline</description>
          <population>The analysis was performed on the same population as previously (i.e. ITT population excluding the patients who didn't have baseline and/or post-baseline value).</population>
          <units>percentage of mL/cmH2O</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.6" spread="35.26"/>
                    <measurement group_id="O2" value="126.6" spread="35.76"/>
                    <measurement group_id="O3" value="98.6" spread="35.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in detrusor compliance was analyzed using a three-way analysis of covariance (ANCOVA) including 3 variables as fixed effects:
treatment group (alfuzosin 0.1 mg/kg/day, alfuzosin 0.2 mg/kg/day or placebo),
age/formulation group (2-7 years of age on solution, 8-16 years of age on solution or 8-16 years of age on tablets),
anticholinergic/antimuscarinic use (yes or no),
and using centered baseline detrusor compliance as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7889</p_value>
            <p_value_desc>P-value was adjusted for multiplicity using the Hochberg procedure. The a priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7889</p_value>
            <p_value_desc>P-value was adjusted for multiplicity using the Hochberg procedure. The a priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Symptomatic Urinary Tract Infection (UTI) Episodes</title>
        <description>When a patient presented with symptoms such as pain, fever or hematuria (discretion of the Investigator), an urinalysis was performed including a dipstick and a quantitative urine culture.
A symptomatic UTI was defined as the presence of symptoms and a positive culture with &gt; 100 000 Colony Forming Units (CFUs) with a single organism.</description>
        <time_frame>12 weeks (double blind treatment period)</time_frame>
        <population>The analysis was performed on the intent-to-treat (ITT) population. All randomized patients were included in the analysis in the treatment group to which they were allocated as per randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Alfuzosin 0.1 mg/kg/Day</title>
          </group>
          <group group_id="O3">
            <title>Alfuzosin 0.2 mg/kg/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Symptomatic Urinary Tract Infection (UTI) Episodes</title>
          <description>When a patient presented with symptoms such as pain, fever or hematuria (discretion of the Investigator), an urinalysis was performed including a dipstick and a quantitative urine culture.
A symptomatic UTI was defined as the presence of symptoms and a positive culture with &gt; 100 000 Colony Forming Units (CFUs) with a single organism.</description>
          <population>The analysis was performed on the intent-to-treat (ITT) population. All randomized patients were included in the analysis in the treatment group to which they were allocated as per randomization.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No symptomatic UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>One symptomatic UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two symptomatic UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Symptomatic Urinary Tract Infection (UTI) Episodes</title>
        <description>Symptomatic UTI episodes were assessed similar to the previous outcome measure but for a longer follow-up period.</description>
        <time_frame>52 weeks (double blind treatment period + open label extension treatment period)</time_frame>
        <population>The analysis was performed on the exposed population (i.e. all patients who received at least one dose of Alfuzosin regardless of the amount of treatment received). It included 3 + 3 patients treated during the 1st treatment period only, 26 + 28 patients treated during the 2nd treatment period only and 54 + 55 patients treated during both periods.</population>
        <group_list>
          <group group_id="O1">
            <title>Alfuzosin 0.1 mg/kg/Day</title>
          </group>
          <group group_id="O2">
            <title>Alfuzosin 0.2 mg/kg/Day</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Symptomatic Urinary Tract Infection (UTI) Episodes</title>
          <description>Symptomatic UTI episodes were assessed similar to the previous outcome measure but for a longer follow-up period.</description>
          <population>The analysis was performed on the exposed population (i.e. all patients who received at least one dose of Alfuzosin regardless of the amount of treatment received). It included 3 + 3 patients treated during the 1st treatment period only, 26 + 28 patients treated during the 2nd treatment period only and 54 + 55 patients treated during both periods.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No symptomatic UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>One symptomatic UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two symptomatic UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Three symptomatic UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Four symptomatic UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events (AE) regardless of seriousness or relationship to drug, spanning from signature of the Informed Consent Form up to the last visit were collected.</time_frame>
      <desc>The analysis was performed on the exposed population (i.e. all patients who received at least one dose of Alfuzosin, whatever the study period and regardless of the amount of treatment received) and included all AE that developed/worsened during the 'on treatment period' (i.e. from first dose up to 2 days after the last dose).</desc>
      <group_list>
        <group group_id="E1">
          <title>Alfuzosin 0.1 mg/kg/Day</title>
        </group>
        <group group_id="E2">
          <title>Alfuzosin 0.2 mg/kg/Day</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDra 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>ARNOLD-CHIARI MALFORMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>VENTRICULOPERITONEAL SHUNT MALFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>MALNUTRITION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>TETHERED CORD SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>URETHRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>TONSILLAR HYPERTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DECUBITUS ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDra 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months after trial completion, the investigators can publish the results. Prior to publication, the sponsor shall review the manuscript and can request changes, provided they do not jeopardize the accuracy and/or the scientific value of the publication. The approval is given in writing by the sponsor, not to exceed 90 days.
To protect by a property right any information the sponsor can postpone the publication, for a period not to exceed 18 months.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi</organization>
      <email>Contact-US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

